Actively Recruiting
Neuroinflammation, White Matter Integrity, and Alzheimer's Biomarkers in Corticobasal Syndrome
Led by Jennifer Whitwell · Updated on 2025-07-07
80
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
Sponsors
J
Jennifer Whitwell
Lead Sponsor
N
National Institute on Aging (NIA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research aims to understand inflammation and damage to the brain's white matter in people with corticobasal syndrome (CBS), a disorder that affects movement, thinking, and behavior. The study will explore if these two processes are connected by using brain imaging and blood tests to measure inflammation and other markers. Researchers will also compare different patient groups, including those with Alzheimer's disease biomarkers and healthy individuals, to learn more about CBS and related brain changes. Participants will undergo several imaging scans, including PET scans using specific tracers like C-11 ER176 to detect inflammation, C-11 PiB for amyloid protein, and AV1451 Tau for tau protein. Advanced MRI techniques will measure white matter structure. Blood samples will be collected to analyze markers related to nerve injury, inflammation, and tau protein. The study includes groups of CBS patients with and without Alzheimer's biomarkers and healthy volunteers for comparison. During the study, participants will have brain scans and provide blood samples to assess inflammation, brain structure, and specific protein markers. Researchers will track these outcomes over approximately 4 to 5 years. The main measure is the PET imaging of neuroinflammation and white matter integrity. Secondary measures include blood plasma tests for inflammation and tau proteins. This long-term monitoring will help understand CBS's underlying brain changes and their relation to inflammation.
CONDITIONS
Brief Title
Imaging Studies in Corticobasal Syndrome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Meet possible or probable corticobasal syndrome criteria
You will not qualify if you...
- MRI contraindicated due to implanted device or severe claustrophobia
- Concurrent illnesses or brain abnormalities that explain CBS symptoms
- Mutation in the progranulin gene
- Prior anti-amyloid beta therapy
- Pregnant women
- Taking daily anti-inflammatory medications (NSAIDs, corticosteroids, etc.)
- Generalized inflammatory conditions treated with immunosuppressive or anti-inflammatory medication within 2 weeks of scanning
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 4 to 5 years
Participants undergo PET scans and blood sampling to assess neuroinflammation, amyloid and tau protein presence, and white matter integrity.
Multiple imaging and blood sample visits over several years
Duration - Approximately 4 to 5 years
Participants are monitored over several years to evaluate changes in neuroinflammation and white matter integrity.
Periodic assessments during study duration
Trial Site Locations
Total: 1 location
1
Mayo Clinic
Rochester, Minnesota, United States, 55905
Actively Recruiting
Research Team
M
Megan J Meyer, M.B.A.
S
Sarah M Boland, CCRP
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here